are glp-1 drugs safe weight-loss for older adults? As GLP-1 Use Expands, Long-Term
Description
The median total duration of protection from FDA approval, when accounting for both pre- and post-approval patents and regulatory exclusivities, was 18.3 years (IQR: 16.0-19.4) (Figure 2)
Wilmington, DE: AstraZeneca Pharmaceuticals LP;2019
doi: 10.1111/dom.13137 34 TrujilloJMNufferWSmithBA
17,18 A post hoc analysis of LOOK AHEAD trial data found that participants who achieved at least a 10% body weight loss in the first year had a 21% lower rate of major adverse cardiac events
F.LingvayI.et al (2021)
